CoChat

ERα negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor

Open access
Fan, Jiang, Yin, Wen-Jin, Lu, Jin-Song, Wang, Lei, Wu, Jiong, Wu, Feng-Ying, Di, Gen-Hong, Shen, Zhen-Zhou, Shao, Zhi-Min · 2008 · Journal of Cancer Research and Clinical Oncology

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

Purpose Estrogen receptor alpha (ER alpha) mediates the growth stimulation of estrogen in breast cancer cells and is a useful predictive factor for response to endocrine therapy. It is reported that ER alpha was induced in ER alpha negative breast cancer cells by both DNA methyltransferase-1 (DNMT1) inhibitor 5-aza-2'-deoxycytidine (AZA) and histone deacetylase (HDAC) inhibitor trichostatin A (TSA). However, whether the breast cancer cells with induced ER alpha restore response to endocrine therapy requires to be further researched.Patients and methods Reverse transcriptase-polymerase chain reaction (RT-PCR) method was used to explore the change in the mRNA of ER alpha, PR and pS2 in the ER alpha negative breast cancer cells MDA-MB-435 treated with two chemicals (AZA + TSA). Water-soluble tetrazolium salt-8 (WST-8) method was used to study the proliferation rate of the breast cancer cells. Flow cytometer (FCW) was used to analyze the distribution of cell cycle of these breast cancer cells. Some xenograft models in nude mice were used to further study the results we found in vitro.Results In this study we observed that the mRNA of ER alpha, PR and pS2 in the ER alpha negative breast cancer cells MDA-MB-435 was re-expressed by treatment with AZA + TSA. The proliferation assay analysis showed AZA + TSA suppressed the proliferation of MDA-MB-435 cells, which were further suppressed by addition of 4-OH Tamoxifen (4-OHT). On the contrary, the proliferation of cells treated with 4-OHT alone showed no difference compared with the vehicle control. Cell cycle analysis showed AZA + TSA treated cells showed S phase arrest, which was partially attenuated by addition of estradiol (E2); furthermore, the effect of E2 on stimulation of cell cycle could be reversed by 4-OHT in the treated cells with induced ER alpha. In vivo experiment xenograft volume of MDA-MB-435 cells treated with AZA + TSA was smaller than that of the control (P < 0.01), and the xenograft of AZA + TSA treated cells was further suppressed by ovariectomy (P < 0.01).Conclusions Our data indicate that DNMT1 inhibitor AZA and HDAC inhibitor TSA play important roles in restoring sensitivity of the ER alpha negative breast cancer cells to endocrine therapy in vitro and in vivo.

Overview

Integrity signals

Registry

Crossref · 10.1007/s00432-008-0354-x

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 28 references

Research works printed but not linked: 2

  1. Keen JC, Yan L, Mack KM, Pettit C, Smith D, Sharma D, Davidson NE (2003b) A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine. Breast Cancer Res Treat 81(3):177–186 · DOI
  2. Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, Davidson NE (2001b) Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res 61(19):7025–7029

Cited by

See all 130

Metadata

Authors
Fan, J., Yin, W.-J., Lu, J.-S., Wang, L., Wu, J., Wu, F.-Y., Di, G.-H., Shen, Z.-Z., & Shao, Z.-M.
Affiliations
Fudan University (CN)
Corresponding author
Shao, Zhi-Min
Venue
Journal of Cancer Research and Clinical Oncology
Published
2008-02-09
Volume
134
Issue
8
Pages
883-890
ISSN
  • 0084-5353 (ISSN-L)
  • 0171-5216
  • 1432-1335
OpenAlex
W2055873602
Cited by
129
References
28
Citations by year
2026: 3 · 2025: 6 · 2024: 2 · 2023: 4 · 2022: 5 · 2021: 9 · 2020: 5 · 2019: 4 · 2018: 6 · 2017: 5 · 2016: 11 · 2015: 8 · 2014: 10 · 2013: 7 · 2012: 8
FWCI
6.84
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Journal of Cancer Research and Clinical Oncology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
cancer, estrogen receptor alpha, endocrine therapy resistance, decitabine, histone deacetylase inhibition, trichostatin A, combination therapy, tamoxifen, cell cycle arrest, MDA-MB-435 cells, xenograft tumor growth, ovariectomy, breast cancer
MeSH terms
Trefoil Factor-1, DNA (Cytosine-5-)-Methyltransferase 1, Decitabine, Animals, Azacitidine, Breast Neoplasms, DNA (Cytosine-5-)-Methyltransferases, Enzyme Inhibitors, Estradiol, Estrogen Antagonists, Estrogens, Female, Flow Cytometry, Humans, Hydroxamic Acids, Receptors, Progesterone, RNA, Messenger, Tamoxifen, Reverse Transcriptase Polymerase Chain Reaction, Xenograft Model Antitumor Assays, Tumor Suppressor Proteins, Cell Line, Tumor, Estrogen Receptor alpha, Cell Proliferation, Mice, Histone Deacetylase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ERα negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor. https://app.cochat.ai/papers/10.1007/s00432-008-0354-x
The paper
Fan, J., Yin, W.-J., Lu, J.-S., Wang, L., Wu, J., Wu, F.-Y., Di, G.-H., Shen, Z.-Z., & Shao, Z.-M. (2008). ERα negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-008-0354-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.